(Total Views: 255)
Posted On: 09/29/2017 10:31:15 AM
Post# of 72447
ZGNX market cap 728 Million. They announced a phase III clinical trial success today, for a drug that treats a rare form of childhood epilepsy. Stock up 125% this morning.
I'm happy that finally there is something to treat this horrible syndrome.
Now let's compare:
ZGNX: 1 phase III success for a drug that treats a rare syndrome in children.
IPIX: Phase II's for Prurisol, Kevetrin, Brilacidin-OM, Brilacidin-UP, all sucessful; Bril-ABSSSI on hold pending funding.
Market cap: 97.85 million.
Think about what were happen if even ONE of the IPIX drugs mentioned above were to have a successful Phase III clinical trial. Think about how much larger IPIX's market would be for that drug than for a rare childhood syndrome.
Then multiply by the 5 drugs currently in clinical trials.
I'm happy that finally there is something to treat this horrible syndrome.
Now let's compare:
ZGNX: 1 phase III success for a drug that treats a rare syndrome in children.
IPIX: Phase II's for Prurisol, Kevetrin, Brilacidin-OM, Brilacidin-UP, all sucessful; Bril-ABSSSI on hold pending funding.
Market cap: 97.85 million.
Think about what were happen if even ONE of the IPIX drugs mentioned above were to have a successful Phase III clinical trial. Think about how much larger IPIX's market would be for that drug than for a rare childhood syndrome.
Then multiply by the 5 drugs currently in clinical trials.
(6)
(0)
